Dialysis giant DaVita could end up losing up to $400 million and be forced to shutter clinics if California voters approve a controversial ballot measure in Tuesday’s midterm elections.
shelled out $66.6 million of the more than $110 million spent by the industry lobbying against the measure. Proposition 8, if passed Tuesday, would cap the amount of money dialysis providers in the state can earn on certain patients.
DaVita operates 292 clinics in California and more than 2,500 clinics nationwide. It reported revenue of more than $2.8 billion in the second quarter.
There’s “certainly a possibility” that it could pass, said Frank Morgan, managing director and healthcare services equity researcher at RBC Capital Markets. He has a “market perform” rating on the stock. If the measure passes, “it would be extremely disruptive to the industry and the state.”
Dialysis is big business
Pushed by the Service Employees International Union, the measure applies to rates charged to patients who don’t have federal insurance provided by Medicare or Medicaid. The programs cover treatment for the majority of people on dialysis in the state, often paying a pre-determined set fee for treatment. But individual health insurers usually have to negotiate rates with dialysis providers, sometimes paying several times the rates charged Medicare.
The ballot proposition would limit the revenue earned, or roughly the rates privately insured patients are charged, for dialysis treatment to 115 percent of the costs to provide the care. Anything above that amount would be put back on dialysis providers, which would be forced to give insurers or patients rebates to make up the difference.
Supporters of the proposal say one way the reimbursements could benefit patients is in the form of lower premiums, Erin Trish, a research professor at the USC Price School of Public Policy, told CNBC.
“Ultimately, the heart of this proposition is kind of rooted in a belief that the private payments are too high,” said Trish, whose research focuses on health insurance markets in the U.S. “It’s not fair that the rates are so much higher than Medicare.”
DaVita spokeswoman Alicia Patterson said “Prop 8 will limit patients’ access to live saving dialysis.” She also pointed to a coalition of 160 medical professionals, clinics and business groups that say it could have far-reaching implications across the state, including clinic closures.
The “No Prop 8” group calls it a dangerous measure that could jeopardize access to dialysis care that patients need to survive.
“California Proposition 8 sets severely low limits on what insurance companies are required to pay for dialysis care,” the coalition says on its website. “These limits do not cover the cost of providing care, forcing many dialysis clinics to cut back services or even close.”
Taking on the proposition
Matthew Gillmor, a senior research analyst at Baird who estimates it could cost DaVita $400 million a year, said lobbyists in Sacramento don’t expect the measure to pass. He cited the millions of dollars the dialysis industry has spent fighting it and prior failures on similar proposals.
This year’s initiative is similar to proposition 61, which targeted high drug prices and ultimately failed two years ago. He said this initiative may have a harder time because voters may deem the topic too complex or not as pertinent to their lives.
An estimated 31 million people in the U.S. have chronic kidney disease, according to a 2016 report from the American Kidney Fund, and is the ninth leading cause of death.
“It’s not a Joe-six-pack issue” like drug pricing, Gillmor told CNBC.
According to a recent poll conducted by SurveyUSA, of the residents likely to vote on the measure, 47 percent said they would support it while 34 percent were opposed.
Despite some doubt about the initiative, Gillmor said DaVita is “taking the threat extremely seriously.”
The vote will likely cap a rocky year for DaVita, which was forced to pay nearly $400 million to the families of three of its dialysis patients in wrongful death lawsuits, and $270 million to settle allegations of Medicare fraud.
DaVita, which has a market cap of more than $11 billion, has seen its shares rise more than 14 percent over the last 12 months.